0      0


Bimekizumab in Patients with Psoriatic Arthritis: 3-Year Results for Overall and Tumor Necrosis Factor Inhibitor (TNFi)-Naïve Populations from a Phase 2b Open-Label Extension Study


‐ Mar 19, 2022 8:30am

You must be logged in and own this session in order to post comments.